Methylation signature of lymph node metastases in breast cancer patients. by Barekati, Z. et al.
Barekati et al. BMC Cancer 2012, 12:244
http://www.biomedcentral.com/1471-2407/12/244RESEARH ARTICLE Open AccessMethylation signature of lymph node metastases
in breast cancer patients
Zeinab Barekati1, Ramin Radpour1, Qing Lu2, Johannes Bitzer3, Hong Zheng4,5, Paolo Toniolo6, Per Lenner7
and Xiao Yan Zhong1*Abstract
Background: Invasion and metastasis are two important hallmarks of malignant tumors caused by complex genetic
and epigenetic alterations. The present study investigated the contribution of aberrant methylation profiles of
cancer related genes, APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14 (ARF), P16 (CDKN2A), P21 (CDKN1A), PTEN, and
TIMP3, in the matched axillary lymph node metastasis in comparison to the primary tumor tissue and the adjacent
normal tissue from the same breast cancer patients to identify the potential of candidate genes methylation as
metastatic markers.
Methods: The quantitative methylation analysis was performed using the SEQUENOM’s EpiTYPER™ assay which
relies on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
Results: The quantitative DNA methylation analysis of the candidate genes showed higher methylation proportion
in the primary tumor tissue than that of the matched normal tissue and the differences were significant for the
APC, BIN1, BMP6, BRCA1, CST6, ESR-b, P16, PTEN and TIMP3 promoter regions (P<0.05). Among those candidate
methylated genes, APC, BMP6, BRCA1 and P16 displayed higher methylation proportion in the matched lymph node
metastasis than that found in the normal tissue (P<0.05). The pathway analysis revealed that BMP6, BRCA1 and P16
have a role in prevention of neoplasm metastasis.
Conclusions: The results of the present study showed methylation heterogeneity between primary tumors and
metastatic lesion. The contribution of aberrant methylation alterations of BMP6, BRCA1 and P16 genes in lymph
node metastasis might provide a further clue to establish useful biomarkers for screening metastasis.
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Breast cancer is one of the most common malignancies
with a high mortality rate among women [1]. Breast
cancer, a heterogeneous disease, presents various patho-
logical signs such as axillary lymph node metastasis
which is associated with a high risk of recurrence and
considered as an important prognosis factor in the early
stages of the disease [2,3]. Invasion and metastasis are
two important hallmarks of malignant tumors asso-
ciated with complex genetic and epigenetic alterations
that allow tumors to disseminate throughout lymphatics* Correspondence: zhongx@uhbs.ch
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reproduction in any medium, provided the oror blood vessels, giving rise to the colonization and
growth of metastatic cells in distant organs [4-6]. Con-
sidering that tumor dissemination is an early event in
breast cancer [7], genetic and epigenetic analysis of
tumors and metastatic lesions could provide results for
biomarker discovery and may improve diagnosis, prog-
nosis and proper management of the treatment for
breast cancer patients.
The contribution of aberrant DNA hypermethylation of
cancer related genes to the transcriptional silencing and
carcinogenesis has been demonstrated in different diseases
including different cancer types [7,8]. The methylation
profile of genes involved in critical molecular processes
such as cell cycle control, DNA repair and angiogenesis in
breast cancer has been investigated [9-12]. Since thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumor cells to the lymph nodes in breast cancer, primary
tumor signatures has been considered as surrogate for
lymph node metastasis. However, this persuasion has re-
cently been controversial especially in the context of DNA
methylation pattern from primary to metastasis in breast
cancer [9,10,13]. According to best of our knowledge
genome-wide DNA methylation was reported in few
metastatic breast cancer cell lines ,however, methylation
pattern of individual candidate genes in both the primary
and lymph node metastases has been explored in clinical
specimens [14,15]. Therefore the profile of metastasis in
breast cancer patients is less characterized and poorly
understood which needs further studies to understand the
relationship between epigenetic alteration and metastases
in breast cancer.
Our previous approach revealed methylation signatures
of 42, 528 CpG sites from 22 breast cancer candidate
genes that demonstrated promoter hypermethylation of
10 genes involved in cell cycle and DNA repair, invasion
and metastasis, cell proliferation, signal transduction
and cell detoxification [16]. Moreover, we have shown
hypermethylation of the two additional genes involved
in TP53 regulatory pathway in the breast cancer patients
[17,18]. The significance of using these hypermethylated
genes as circulating biomarkers has been explored as
well [18]. The present study investigated the contribution
of significant aberrant methylation profile of twelve
cancer related genes from the aforementioned studies
(APC, BIN, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14,
P16, P21, PTEN and TIMP3) in matched axillary lymph
node metastasis in comparison to the primary tumor tis-
sue and the adjacent normal tissue from the same breast
cancer patients to identify the potential of aberrant
methylation profile of the candidate genes as metastatic
signature.
Methods
Sampling and pathological classification
The study was approved by the local institutional review
board (Ethic commission beider Basel, Sichuan Univer-
sity China). Written consent forms were collected from
all patients who were involved in this study. Staging andTable 1 Clinical characteristics of the studied cohort
Total
no.
of
patients
Breast cancer
tumor type
Age
mean ±
S.D.
(range)
Pathologic stage No. o
patien
with
distan
metas
IDC ILC Early
(I,II)
Late
(III)
24 20 4 48 ± 9.53
(33-69)
14 10 0
IDC, Invasive Ductal Carcinoma; ILC, Invasive Lubular Carcinoma; ER, Estrogen Recepgrading was evaluated according to the WHO histo-
logical classification. DNA was isolated from 65 samples
including matched primary tumors tissue, matched nor-
mal tissue and their matched lymph node metastasis of
24 chines patients with breast cancer. The present co-
hort included 17 matched normal breast tissues that
were collected at least 4 cm away from the tumor site
and were confirmed as normal tissue by pathologist. The
axillary lymph nodes were removed at the same surgery.
Part of the samples was embedded using OCT (Optimal
Cutting Temperature, Sakura Finetek, U.S.A) and stored
in liquid nitrogen. The above procedures were com-
pleted within 20 minutes after peeling preparation. The
samples were then stored at -80o. The frozen tissues
were sectioned in 4 μm thickness and were submitted
for hematotoxylin and eosin staining study. According to
pathological tumor type and immunohistochemistry
staining, studied cohort consisted of patient’s with Inva-
sive Ductal Carcinoma (IDC) and Invasive Lobular Car-
cinoma (ILC). Breast cancer characteristics, such as
staging, histological grading, and hormone receptor ex-
pression from the breast cancer patients are listed in
Table 1.
The entirely neoplastic and adjacent normal frozen
sections were subjected for DNA extraction. Five to ten
sections with 90% neoplastic coverage applied for DNA
extraction, and last section was checked for the correct
characterization, using the High Pure PCR Template
Preparation Kit (Roche, Germany). The rest of the sam-
ples were fixed in 10% buffered formalin for immunohis-
tochemical staining study.
The analysis for the detection of estrogen receptor
(ER), progesterone receptor (PR) and HER2/neu
(C-ErbB-2) proteins was carried out using primary anti-
bodies for Rabbit anti-human estrogen receptor mono-
clonal antibody (clone sp1, Roche), Rabbit anti-human
progesterone receptor monoclonal antibody (clone sp2,
Roche), Rabbit anti-human HER-2/neu monoclonal anti-
body (clone 4B5, Roche). Then slide stainings were pro-
cessed using ultraView Universal DAB Detection Kit
(Ventana Medical Systems Inc, Tucson, AZ) (Figure 1).
The ER, PR and HER-2/neu were analyzed following
ASCO/CAP Guidelines.f
ts
ce
tasis
Histological grade ER
positive
patients
PR
positive
patients
C-ERB2
positive
patients1 2 3
1 5 18 19 12 12
tor; PR, Progestron Receptor.
Figure 1 Hematotoxylin and eosin staining (H&E) and immunohistochemical staining for estrogen receptor (ER), progesterone receptor
(PR) and HER2/neu proteins (400X). (a) Ductal carcinoma. (b) Lobular carcinoma.
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mass array on MALDI-TOF silico-chip
The SEQUENOM’s EpiTYPER™ assay is a methylation
quantification method which relies on MALDI-TOF MS
[19]. The theory and practice of this approach for DNA
methylation quantification has been confirmed by previ-
ous studies [16,20,21]. In the current study, this assay
was used to quantify the methylation of APC, BIN1,
BRCA1, BMP6, CST6, ESR-b, GSTP1, P14, P16, P21,
PTEN and TIMP3 promoter regions.
Bisulfite treatment
Bisulfite conversion of the target sequences was per-
formed according to the instruction of the EpitectW
Bisulfite Kit (QIAGEN AG, Basel, Switzerland).
Primer designing and PCR-tagging for EpiTYPERTM assay
To design PCR primer for the candidate genes, CpG
density and CpG sites of the twelve targeted sequences
were analyzed. According to our previous publications,
we used the same primer sequences which were tagged
with T7-promoter for the reverse and a 10 mer
sequences to the forward primer to balance the PCR
condition and primer pairs can cover the promoter
regions with the most CpG sites using MethPrimer. The
primer sequences, annealing temperatures (Ta) and PCR
conditions are described in Additional file 1.
In vitro transcription, T-cleavage assay and mass
spectrometry
Unincorporated dNTPs were dephosphorylated by add-
ing 1.7μL H2O and 0.3 units of shrimp alkaline phos-
phatase (SAP; SEQUENOM, Inc., San Diego, CA). Thereaction mixture was incubated at 37°C for 20 minutes
and the SAP was then heat inactivated for 10 minutes at
85°C. Typically, 2μL of the PCR were used directly as a
template in a 5μL transcription reaction. Twenty units
of T7 R&DNA polymerase (Epicentre, Madison, WI)
were used to incorporate dTTP in the transcripts. Ribo-
nucleotides were used at 1 mmol/L and the dNTP sub-
strate at 2.5 mmol/L. In the same step, the in vitro
transcription RNase A (SEQUENOM) was added to
cleave the in vitro transcript (T-cleavage assay). The
mixture was further diluted with H2O to a final volume
of 27μL. Twenty-two nanoliters of cleavage reaction
were robotically dispensed (nanodispenser) onto silicon
chips preloaded with matrix (SpectroCHIP; SEQUENOM,
San Diego). Mass spectra data were collected using a
MassARRAY Compact MALDI-TOF (SEQUENOM)
and spectra’s methylation proportions were generated
by the Epityper software v1.0 (SEQUENOM, San
Diego).
Cell signaling and pathway analysis
Gene networks and canonical pathways displaying
hypermethylated genes in lymph node metastasis were
identified using the Pathway StudioW software version
7.1 (Mammal) database (Ariadne Genomics, Inc., Rockville,
USA). The functional analysis identified the biological per-
spective of the genes that were most relevant to the data
sets and facilitated the understanding beyond their func-
tional link to breast neoplasm and metastasis.
Statistical methods
Data analysis was performed using the SPSS software
(Statistical Software Package for Windows, version 19).
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Smirnov test that demonstrated our data set was not
normally distributed (P< 0.001). Quantitative methyla-
tion profile of the twelve candidate genes were com-
pared among primary tissue, adjacent matched normal
tissue and their matched lymph node metastasis using
the two-way hierarchical cluster analysis. The CpG sites
for each gene were clustered based on pair-wise Euclid-
ean distances and linkage algorithm for all studied sam-
ples according to the previously developed method by
Gene Expression Statistical System (GESS) version
7.1.19 (NCSS, Kaysville, Utah, USA) and the statistical
differences between mean methylation quantity of the
informative CpG sites per genes were identified using
Mann-Whitney-U-Test. The non-parametric Spearman's
rho test was performed to find out significance clinical-
pathological parameters.Results
Quantitative methylation profiles of the 12 breast cancer
candidate genes promoter using MALDI-TOF MS
The methylation profiles of 12 breast cancer candidate
genes in matched primary tumors, normal tissue and
their matched lymph node metastasis from 24 breast
cancer patients were assessed. For all the genes, one
amplicon per gene and 250 CpG sites in total per sample
(total of 16,250 sites in 65 analyzed samples) were ana-
lyzed (Table 2; Additional file 2.)
The different levels of methylation between studied
samples were identified using the two-way hierarch-
ical cluster analysis. The methylation cluster analysisTable 2 High-throughput methylation analysis of CpG sites p
Genes Amplicon
size (bp)
Total
No.
of CpG
sites in
amplicon
No.
of
analyz
CpG s
in am
APC 420 26 1
BIN1 330 32 1
BMP6 397 37 2
BRCA1 413 30 1
CST6 445 49 1
ESR-b (ER beta) 374 30 1
GSTP1 381 23 1
P14 425 36 2
P16 (CDKN2A) 580 62 3
P21 (CDKN1A) 419 30
PTEN 451 34 2
TIMP3v 441 51 4
The in silico digestion was performed for the T-cleavage assay. The percentage of to
composite sites (two or more adjacent CpG sites fall within one fragment, or whenfor each individual studied gene is illustrated in
Additional file 2.
Methylation alterations of the primary tumor tissue
Hierarchical cluster analysis profiling of the promoter
alterations and the significance of the alterations are
shown in Figure 2(a) for the 12 studied genes.
Methylation quantification of the 12 candidate genes
revealed significantly higher methylation proportion for
promoter regions of APC, BIN1, BMP6, BRCA1, CST6,
ESR-b, P16, PTEN and TIMP3 in primary tumor tissue
versus matched normal tissue (P< 0.05, P< 0.05,
P< 0.01, P< 0.0001, P< 0.01, P< 0.01, P< 0.05,
P< 0.05, P< 0.01 ; respectively). Methylation analysis of
GSTP1, P14 and P21 in primary tumor tissue showed
slightly higher methylation proportion in comparison to
the matched normal tissue, however, the differences
were not significant (Figure 2b).Methylation alterations of the matched lymph node
metastasis
Comparison of methylation profiles of the 12 breast can-
cer candidate genes in the paired lymph node metastasis
to the matched normal tissue showed significantly
higher methylation levels for APC, BMP6, BRCA1 and
P16 genes (P< 0.05 and P< 0.01, P< 0.0001, P< 0.05;
respectively). The lymph node metastasis was even more
hypermethylated for BMP6 than the primary tumor tis-
sue (P< 0.05). The promoter region of BIN1, BMP6,
BRCA1, GSTP1, P14 and TIMP3 showed significantly
lower methylation ratio in the lymph node metastasiser amplicon for the 12 candidate genes
ed
ites
plicon
No. of analyzed CpG sites per amplicons
Single sites Composite sites
1 9 2
2 3 9
6 9 17
5 10 5
9 11 8
3 6 7
6 11 5
2 5 17
8 12 26
9 8 1
9 10 19
0 12 38
tal CpG sites in the amplicon is divided into single sites (single CpG sites) and
fragment masses are overlapping).
Figure 2 a) Double dendrogram presents the methylation profiles of the twelve candidate genes in tumor tissue, matched normal
tissue and lymph nodes metastasis (Red clusters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient
between red and yellow indicates methylation ranging from 0-100). b) Comparison between quantitative analysis (0%-100%) of methylation
for the candidate genes in the studied cohort (* significant correlation; Mann-Whitney U Test).
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P< 0.01, P< 0.05, P< 0.05; respectively).
Comparing the lymph node metastasis to the matched
normal tissue, the former revealed differentially lower
methylation ratio for BIN1, GSTP1 and P14 promoter
regions (P< 0.05, P< 0.01, P< 0.05; respectively)
(Figure 2).Relationship of methylation alterations within the promoter
region of 12 breast cancer candidate genes and
clinicopathological parameters
Clinicopathological parameters with the methylation pro-
portion of the 12 candidate genes in primary tumor tissue
and matched lymph node metastasis were analyzed. The
analyses showed significant correlation between higher
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grade in the primary tumor tissue (Spearman's rho test;
P< 0.05). The higher methylation proportion of BIN1
showed significant correlation with expressed ER in pri-
mary tumor tissue (Spearman's rho test; P< 0.01). Methy-
lated TIMP3 revealed significant correlation to the primary
tumor tissue lacking expression of PR (Spearman's rho test;
P< 0.05). The increase of methylation of P21 showed an
inverse correlation with the expression of C-ERB2 in the
primary tumor tissue (Spearman's rho test; P< 0.05). We
could not find any significant correlations between methy-
lation alterations in either of the matched lymph node me-
tastasis and clinicopathological parameters.
Discussion
Aberrant methylation profiles and silencing of a small
subset of tumor suppressors and cancer related genes
involved in both the primary tumor and lymph node me-
tastasis has been investigated for breast cancer [11,22-24].
Several studies on breast cancer revealed some similarities
and differences between promoter methylation pattern of
the studied genes in primary and lymph node metastatic
[16,19,25]. These investigations highlight the important
role of aberrant promoters’ methylation in the metastatic
process. In the present study, we implemented the methy-
lation signature of the 12 breast cancer candidate genes
(APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14,
P16, P21, PTEN and TIMP3) by comparing lymph nodes
metastasis to their matched primary tumor tissues and
normal tissues from the same breast cancer patients.
The quantitative methylation analysis of the 12 studied
genes in the present cohort showed higher methylationFigure 3 Pathway analysis of the hypermethylated genes in lymph no
association to breast carcinogenesis and neoplasm metastasis.proportion for the primary tumor tissue versus matched
normal tissue and the differences were significant for
APC, BIN1, BMP6, BRCA1, CST6, ESR-b, P16, PTEN
and TIMP3 promoter regions (P< 0.05, P< 0.05, P<
0.01, P< 0.0001, P< 0.01, P< 0.01, P< 0.05, P< 0.05,
P< 0.01; respectively). Among the significant methylated
genes, APC, BMP6, BRCA1 and P16 represented higher
methylation proportions in matched lymph node metas-
tasis compared to those of the normal tissue (P< 0.05
and P< 0.01, P< 0.0001, P< 0.05; respectively). Present
findings provided evidence of differences in methylation
status between primary tumors and their corresponding
matched lymph nodes and demonstrated methylation
heterogeneity between primary tumors and metastatic
lesion which are in line with previous reports described
about primary tumor and metastasis in breast, gastric
and colorectal cancers [13,26,27]. The results also indi-
cated that some of the cancer specific changes become
altered over the metastasis procedure. The mechanism
for losing or gaining methylation in lymph nodes meta-
static is still not clear while the alteration of the methy-
lation signature from primary to metastasis might be
due to the adaptation response of the disseminated cells
to the microenvironment at the site of colonization [28].
The molecular function, biological processes and con-
tribution of the studied genes to developing metastasis
were analyzed by ResNetW 7 (Mammal). The pathway
analysis revealed that BMP6, BRCA1 and P16 have a role
in prevention of neoplasm metastasis (Figure 3). The re-
lation of DNA methylation for BRCA1 and P16 with
tumor recurrence has been reported with a high value in
breast cancer patients [29]. Moreover, association of P16de metastasis including their biological processes and
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node invasion has been shown in different studies
[30,31]. Then, the aberrant methylation signatures of
these genes found in the metastatic lymph node can pro-
vide a further clue to establish useful biomarkers for
screening metastasis in breast cancer. Such biomarkers
will need to be additionally explored for the potential
opposing functional effects of specific hypermethylated
CpG sites on transcriptional activity as well as for abso-
lute percent methylation cutoffs for each breast tumor
type that would enable reliable utility of them in the
clinical laboratory setting. The possibility of using these
hypermethylated genes as biomarkers in our previous
study was investigated with the aim of developing a
blood based panel for plasma and serum samples of
breast cancer patients [18]. Thus the detection of these
three hypermethylated genes either as tissue specific bio-
markers or as circulating biomarkers may give insight
into the prognosis and therapeutic management of the
breast cancer patients. Moreover, we identified signifi-
cantly greater hypermethylation proportion of BMP6 in
the lymph node metastasis than their primary tumor tis-
sue (P< 0.05). BMP6 is a member of TGF-β super family
and critically involved in many developmental processes
[32]. Recently, the close association of BMP6 with pro-
gression of tumorigenesis and regulation of invasion for
tumor cells has been reported [33]. It has been assumed
that demethylation of BMP6 and re-expression of this
gene might modulate metastasis and invasion in breast
cancer [34,35].Conclusions
In conclusion, the present study showed aberrant
tumor-specific methylation alterations for APC, BIN1,
BMP6, BRCA1, CST6, ESR-b, GSTP1, P14, P16, P21,
PTEN and TIMP3 in the studied cohort. Additionally,
we identified methylation heterogeneity between primary
tumors and metastatic lesions. The contribution of aber-
rant methylation alterations of BMP6, BRCA1 and P16
genes in lymph node metastasis might provide a further
clue to establish useful biomarkers for screening metas-
tasis, which might improve prognosis and therapeutic
management of the breast cancer patients.Additional files
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